**GHIT Fund Hit-to-Lead Platform (HTLP)**

**Reference Number: GHIT-RFP-HTLP-2025-001**

**RFP Intent to Apply Form**

**Please submit the Intent to Apply (ITA) form via Editorial Manager® (**[**https://www.editorialmanager.com/ghitfund/**](https://www.editorialmanager.com/ghitfund/)**) by 10:00 a.m. Tokyo time on January 10, 2025.** Please do not submit any other documents other than the ITA form to the GHIT Fund. Applicants who submit the ITA document will receive a confirmation email. The GHIT Fund Management Team will conduct an initial eligibility assessment of the partnership and scope. **Only eligible applicants will be invited to submit the full proposal and will receive the proposal templates from the GHIT Fund**.

If applicants have any questions regarding the RFP, please send an email to RFPResponse@ghitfund.org. Please also refer to the Frequently Asked Questions (FAQ) page on the GHIT website: <https://www.ghitfund.org/applyforfunding/investmentfaq/en>.

***Table of contents***

[1. History of Applying for Funding to the GHIT Fund 1](#_Toc180357849)

[2. Project Title 2](#_Toc180357850)

[3. Project Scope 2](#_Toc180357852)

[4. Partnership and Role/Responsibility 2](#_Toc180357853)

[5. Project Summary 3](#_Toc180357854)

[5.1 Project Overview (200 words limit) 3](#_Toc180357855)

[5.2 Independent Scientific Review 3](#_Toc180357856)

[5.3 Global Health Need and Impact (200-word limit) 3](#_Toc180357857)

[5.4 Project Budget: 3](#_Toc180357858)

[6. Compliance Checklist 3](#_Toc180357859)

[7. Agreement/Signature 4](#_Toc180357860)

# History of Applying for Funding to the GHIT Fund

Please provide the project ID number **related to this application,** if you have applied for GHIT funding before.

*Insert Project ID Here*

*\*\*T201X-10X previous proposal decision (i.e. Awarded)\*\**

*\*\*Please specify if this new application is a continuation[[1]](#footnote-2) of a project previously funded by the GHIT Fund\*\**

# Project Title

*Insert Project Title Here*

# Project Scope

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **The proposal is expected to address the following RFP scope components (please refer to the RFP document for eligibility criteria):**  *Please check all that apply*   |  |  | | --- | --- | | **Disease** | | | ☐ Malaria  ☐ Tuberculosis | ☐ Chagas disease  ☐ Visceral leishmaniasis |  Partnership and Roles/Responsibilities **The partnership consists of the following organizations** (please add columns if your partnership consists of more than three organizations).  Please note that the GHIT Fund **requires one of the three lead PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), or TB Alliance, to be included as a Collaboration Partner in HTLP projects.** A partnership with one of the above PDPs must be established at the time of ITA submission.   |  |  |  |  |  | | --- | --- | --- | --- | --- | |  | | **Designated Development Partner\*/**  **Collaboration Partner 1** | **Collaboration**  **Partner 2** | **Collaboration**  **Partner 3** | | Organization Name |  | |  |  | | Organization Type  (e.g., PDP, pharma company, academic institution) |  | |  |  | | Organization Status | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | ☐ Japanese  ☐ Non-Japanese  Please specify the country below.  \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | Organization Address and Phone number |  | |  |  | | Organization Webpage |  | |  |  | | Lead PI (name and job title) |  | |  |  | | Contact Details (email, phone) |  | |  |  | | Role and Responsibility |  | |  |  |   *\* The Designated Development Partner will be the funding recipient and will be responsible for the performance of its Collaborating Partners. A representative of the Designated Development Partner will serve as the primary point of contact with the GHIT Fund and will be responsible for all discussions and negotiations with the GHIT Fund.* Project Summary5.1 Project Overview (200 words limit) Provide an overview of the **two-year project** for which you are requesting funding from the GHIT Fund, including milestones and activities, and the expected outcome/deliverables at the end of the project.   |  | | --- | | *Such as What, Why, Who, When, How, How Much, Milestones, Activities, Deliverables, etc.* |  5.2 Independent Scientific Review If the proposed project has already been reviewed by an established independent scientific or technical advisory committee (such as those established by PDPs), please summarize here.   |  | | --- | |  |  5.3 Global Health Need and Impact (200-word limit) What makes this project unique in addressing global needs and making a significant impact  in the short or long term?   |  | | --- | |  |  5.4 Project Budget: Please indicate the approximate amount of funding in Japanese Yen required to support the proposed project. Please note that the GHIT Fund does not support capital costs. Please provide the currency exchange rate used to calculate the total budget in Japanese Yen, if applicable.   |  | | --- | |  | |

# Compliance Checklist

Please answer the following questions regarding the Designated Development Partner, Collaboration Partner(s), and Principal Investigators who will be involved in the project proposed in this application (“Project”). Please mark ‘Yes’ or ‘No’ and provide explanations as needed. Please note that your answers in this section will be taken into account by the GHIT Fund in it its decision on your application.

|  |  |
| --- | --- |
| 1. Are there any pending or threatened civil, criminal, administrative or regulatory proceedings, actions, suits or investigations (either as a plaintiff or a defendant) that could lead to have an effect on the Project? | ☐ No  ☐ Yes – Please explain: |
| 1. Are sufficient measures in place to ensure that the Project is implemented, controlled, managed, and monitored in compliance with all applicable ethical, legal, regulatory and safety rules and requirements, including applicable international, national, local, industrial and institutional standards? | ☐ No  ☐ Yes – Please explain: |
| 1. Are sufficient measures in place to prevent each of the following?  * Research misconduct[[2]](#footnote-3) * Misuse, misappropriation, or other inappropriate use of grants, donations, contributions, or subsidies[[3]](#footnote-4) | ☐ No  ☐ Yes – Please explain: |
| 1. Please confirm that, to the best of their knowledge, the Designated Development Partner, Collaboration Partner(s), and/or Principal Investigator(s) have not, directly or indirectly supported or promoted, and will use reasonable efforts to ensure that they do not directly or indirectly support or promote, terrorist, criminal or anti-social activities or related training, or money laundering. | ☐ Confirm  ☐ Do not confirm |
| 1. Please confirm that the Designated Development Partner, Collaboration Partner(s) and/or Principal Investigator(s) have never taken any action directly or indirectly offer, pay, promise to pay, or authorize or approve the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any government official in Japan or in any other jurisdiction or any official of any public international organization, for the purpose of influencing official action or securing an improper advantage. | ☐ Confirm  ☐ Do not confirm |
| 1. Please read and acknowledge the “Award Administration and Conditions” described in the RFP. | ☐ Acknowledge  ☐ Do not acknowledge |

# Agreement/Signature

This Intent to Apply form is submitted by:

|  |  |
| --- | --- |
| Name:  Title:  Organization:  Date: |  |
| **Agreement**  We hereby agree that the above information is accurate and true. We understand that any false information provided may result in the revocation of the proposal submitted.  (Signature) | |

[End of Document]

1. *“Continuation project” is a new application of extended or continued research from a project previously funded by the GHIT Fund.* [↑](#footnote-ref-2)
2. In the “Guidelines for Responding to Research Misconduct (Approved by the Minister of Education, Culture, Sports, Science and Technology on August 26, 2014)”, each of the following acts is defined as specific research misconduct:

   (1) Fabrication: making up data or research results, etc.

   (2) Falsification: the manipulation of research materials, equipment, or procedures to alter data or results obtained from research activities

   (3) Plagiarism: appropriating the ideas, analyses, analytical methods, data, research results, research paper(s), or words of other researchers without obtaining the permission of the researchers or giving appropriate credit [↑](#footnote-ref-3)
3. “Misuse” means the use of such funds for purposes other than those originally intended or agreed upon, whether intentionally or through gross negligence. [↑](#footnote-ref-4)